- This study evaluated the anti-angiogenic properties of Suramab, a novel pharmaceutical compound, in a rabbit model of corneal neovascularization. - Rabbits treated with Suramab showed lower neovascularization than controls at 35 days. Suramab was more effective than bevacizumab at reducing neovascularization. - Tests showed Suramab reduces VEGF, bFGF, LYVE-1, and P2X2, which are involved in its anti-angiogenic mechanism of action. - Drug delivery systems are being developed to improve Suramab's performance in treating corneal and retinal neovascularization.